Incannex Healthcare's IHL-42X Shows Promising Phase 2 Results for Sleep Apnea Treatment
Incannex Healthcare Inc. reports significant progress with its IHL-42X treatment for obstructive sleep apnea, achieving up to 83% reduction in apnea events with strong patient-reported outcomes, positioning the company for potential market entry while strengthening its financial position.
Stonegate Capital Partners has updated its coverage on Incannex Healthcare Inc. following the company's significant progress with its IHL-42X asset for obstructive sleep apnea treatment. The Phase 2 study results show both low and high dose groups achieved statistically significant reduction in Apnoea-Hypopnoea Index from baseline compared to placebo, with maximum AHI reductions reaching 83% for the high-dose group and 79% for the low-dose group.
The treatment demonstrated excellent tolerability with no serious adverse events reported during the treatment period across both cohorts. Patient-reported outcomes were equally impressive, with 57.6% of participants reporting perceived improvement in their OSA condition, and 89.5% of those reporting improvement described the change as meaningful to their lives. These results position IXHL favorably as it begins the next steps toward bringing IHL-42X to market.
Incannex has significantly strengthened its financial position through strategic financing arrangements designed to optimize capital structure and minimize dilution. The company utilized proceeds from its ATM to issue approximately $24.7 million worth of shares to repurchase all outstanding Series A Warrants representing 347.2 million potentially dilutive shares. These measures highlight management's proactive approach to capital management, supporting financial flexibility and providing significant visibility.
Beyond the IHL-42X program, Incannex continues to advance other pipeline assets. PSX-001, a psilocybin-based candidate for Generalized Anxiety Disorder, achieved positive results from a Phase 2 proof-of-concept study. The company has secured IND clearance from the FDA and Clinical Trial Authorization from UK regulatory authorities for the PsiGAD2 Phase 2 trial, which will recruit 94 patients across both countries. Additional information about the company's pipeline can be found at https://www.incannex.com.
Meanwhile, IHL-675A, targeting inflammation associated with rheumatoid arthritis, completed patient dosing in its Phase 2 trial with approximately 128 participants. Data from this study is expected in the second half of 2025, with future resources dedicated to a larger U.S. Phase 2 study that could potentially accelerate regulatory approval. The company's diversified pipeline and strong financial position create multiple value drivers for investors seeking exposure to the emerging psychedelic and cannabinoid medicine space.